Literature DB >> 7796979

Non-parallelism of islet amyloid polypeptide (amylin) and insulin gene expression in rats islets following dexamethasone treatment.

H Mulder1, B Ahrén, M Stridsberg, F Sundler.   

Abstract

Islet amyloid polypeptide (IAPP), a novel islet hormone candidate, has been reported to be over-expressed relative to insulin in rats following dexamethasone treatment. In order to investigate the expression of IAPP and insulin following dexamethasone treatment of rats for 12 days, we applied in situ hybridization and immunocytochemistry, allowing us to evaluate islet changes in gene expression and morphology. Tissue concentrations of IAPP and insulin were measured by radioimmunoassay. A low dose of dexamethasone (0.2 mg/kg daily) increased the islet levels of IAPP and insulin mRNA to 249 +/- 13% and 150 +/- 24% of controls, respectively (p < 0.001 and p < 0.01). A high dose of dexamethasone (2.0 mg/kg daily) increased the islet levels of IAPP and insulin mRNA to 490 +/- 13% and 203 +/- 9% of controls, respectively (p < 0.001 and p < 0.001). The pancreatic concentration of IAPP increased more than that of insulin (p < 0.05). Morphometric analysis revealed that dexamethasone treatment induced both hyperplasia and hypertrophy of insulin cells. Changes in the cellular localization of IAPP and insulin mRNA were not observed. Thus, we conclude that the increased level of IAPP mRNA is due to both an increase at the cellular level as well as hyperplasia/hypertrophy of insulin cells. In contrast, the increased level of insulin mRNA appears to be due to hyperplasia/hypertrophy of insulin cells, since insulin gene expression decreased at the cellular level (p < 0.001 vs controls). These observations provide further evidence that IAPP and insulin gene expression are regulated in a non-parallel fashion, which may be relevant to the pathogenesis of non-insulin-dependent diabetes mellitus.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7796979     DOI: 10.1007/bf00410276

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  31 in total

1.  In vivo insulin resistance induced by amylin primarily through inhibition of insulin-stimulated glycogen synthesis in skeletal muscle.

Authors:  S Frontoni; S B Choi; D Banduch; L Rossetti
Journal:  Diabetes       Date:  1991-05       Impact factor: 9.461

2.  Amylin-induced in vivo insulin resistance in conscious rats: the liver is more sensitive to amylin than peripheral tissues.

Authors:  S J Koopmans; A D van Mansfeld; H S Jansz; H M Krans; J K Radder; M Frölich; S F de Boer; D K Kreutter; G C Andrews; J A Maassen
Journal:  Diabetologia       Date:  1991-04       Impact factor: 10.122

3.  Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients.

Authors:  G J Cooper; A C Willis; A Clark; R C Turner; R B Sim; K B Reid
Journal:  Proc Natl Acad Sci U S A       Date:  1987-12       Impact factor: 11.205

4.  Altered islet amyloid polypeptide (amylin) gene expression in rat models of diabetes.

Authors:  D Bretherton-Watt; M A Ghatei; S R Bloom; H Jamal; G J Ferrier; S I Girgis; S Legon
Journal:  Diabetologia       Date:  1989-12       Impact factor: 10.122

5.  Human islet amyloid polypeptide transgenic mice as a model of non-insulin-dependent diabetes mellitus (NIDDM).

Authors:  N Fox; J Schrementi; M Nishi; S Ohagi; S J Chan; J A Heisserman; G T Westermark; A Leckström; P Westermark; D F Steiner
Journal:  FEBS Lett       Date:  1993-05-24       Impact factor: 4.124

6.  Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus.

Authors:  A Lorenzo; B Razzaboni; G C Weir; B A Yankner
Journal:  Nature       Date:  1994-04-21       Impact factor: 49.962

7.  Islet amyloid polypeptide-producing pancreatic islet cell tumor. A clinical and biochemical characterization.

Authors:  M Stridsberg; E Wilander; K Oberg; G Lundqvist; B Eriksson
Journal:  Scand J Gastroenterol       Date:  1992-05       Impact factor: 2.423

8.  Pancreatic beta cell replication induced by glucocorticoids in subhuman primates.

Authors:  A A Like; W L Chick
Journal:  Am J Pathol       Date:  1974-05       Impact factor: 4.307

9.  Calcitonin/calcitonin gene-related peptide transcription unit: tissue-specific expression involves selective use of alternative polyadenylation sites.

Authors:  S G Amara; R M Evans; M G Rosenfeld
Journal:  Mol Cell Biol       Date:  1984-10       Impact factor: 4.272

10.  Influence of islet amyloid polypeptide and the 8-37 fragment of islet amyloid polypeptide on insulin release from perifused rat islets.

Authors:  Z L Wang; W M Bennet; M A Ghatei; P G Byfield; D M Smith; S R Bloom
Journal:  Diabetes       Date:  1993-02       Impact factor: 9.461

View more
  11 in total

1.  Blockade of muscarinic transmission increases the frequency of diabetes after low-dose alloxan challenge in the mouse.

Authors:  B Ahrén; G Sundkvist; H Mulder; F Sundler
Journal:  Diabetologia       Date:  1996-04       Impact factor: 10.122

2.  Human-IAPP disrupts the autophagy/lysosomal pathway in pancreatic β-cells: protective role of p62-positive cytoplasmic inclusions.

Authors:  J F Rivera; T Gurlo; M Daval; C J Huang; A V Matveyenko; P C Butler; S Costes
Journal:  Cell Death Differ       Date:  2010-09-03       Impact factor: 15.828

3.  Islet amyloid polypeptide (amylin) and insulin are differentially expressed in chronic diabetes induced by streptozotocin in rats.

Authors:  H Mulder; B Ahrén; F Sundler
Journal:  Diabetologia       Date:  1996-06       Impact factor: 10.122

4.  Mutation at position -132 in the islet amyloid polypeptide ( IAPP) gene promoter enhances basal transcriptional activity through a new CRE-like binding site.

Authors:  A Novials; E Mato; M Lucas; C Franco; M Rivas; P Santisteban; R Gomis
Journal:  Diabetologia       Date:  2004-07-09       Impact factor: 10.122

Review 5.  Islet amyloid: a complication of islet dysfunction or an aetiological factor in Type 2 diabetes?

Authors:  A Clark; M R Nilsson
Journal:  Diabetologia       Date:  2004-01-13       Impact factor: 10.122

6.  Autophagy defends pancreatic β cells from human islet amyloid polypeptide-induced toxicity.

Authors:  Jacqueline F Rivera; Safia Costes; Tatyana Gurlo; Charles G Glabe; Peter C Butler
Journal:  J Clin Invest       Date:  2014-07-18       Impact factor: 14.808

Review 7.  Islet amyloid in type 2 diabetes, and the toxic oligomer hypothesis.

Authors:  Leena Haataja; Tatyana Gurlo; Chang J Huang; Peter C Butler
Journal:  Endocr Rev       Date:  2008-02-26       Impact factor: 19.871

8.  β-cell dysfunctional ERAD/ubiquitin/proteasome system in type 2 diabetes mediated by islet amyloid polypeptide-induced UCH-L1 deficiency.

Authors:  Safia Costes; Chang-jiang Huang; Tatyana Gurlo; Marie Daval; Aleksey V Matveyenko; Robert A Rizza; Alexandra E Butler; Peter C Butler
Journal:  Diabetes       Date:  2010-10-27       Impact factor: 9.461

9.  β-Cell failure in type 2 diabetes: a case of asking too much of too few?

Authors:  Safia Costes; Ralf Langen; Tatyana Gurlo; Aleksey V Matveyenko; Peter C Butler
Journal:  Diabetes       Date:  2013-02       Impact factor: 9.461

10.  Human islet amyloid polypeptide transgenic mice: in vivo and ex vivo models for the role of hIAPP in type 2 diabetes mellitus.

Authors:  J W M Höppener; H M Jacobs; N Wierup; G Sotthewes; M Sprong; P de Vos; R Berger; F Sundler; B Ahrén
Journal:  Exp Diabetes Res       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.